Overall Score

Revenue Model

The company still appears to monetize a differentiated medtech product set, but the current revenue base remains modest relative to valuation.

Gross margin remains strong at 71.5%, indicating the core product economics are healthy even though overall profitability is still negative.

Profitability

TTM operating margin is -16.0% and net margin is -18.3%, showing the business is still not profitable on an operating basis.

Returns remain negative across ROA (-6.2%), ROE (-9.5%), and ROIC (-6.0%), reinforcing that capital is not yet generating positive earnings.

Balance Sheet

Liquidity remains solid with a current ratio of 3.9x and quick ratio of 3.1x, giving the company flexibility to fund operations.

Leverage is manageable with debt-to-equity at 0.29x and net debt to EBITDA still negative, supported by a cash balance of $2.29 per share.

Cash Flow

Operating cash flow is positive, but free cash flow conversion is weak with FCF yield near 0.25% and FCF-to-OCF at 65.2%.

Working capital intensity remains high, with a cash conversion cycle of 377 days driven by slow inventory turnover and long receivables collection.

Valuation

The stock still screens expensive on sales at 10.7x EV/Sales and extremely expensive on cash flow at over 400x P/FCF.

Negative earnings and negative EBITDA make traditional earnings-based valuation metrics less supportive.